Eli Lilly (NYSE:LLY) said today that the FDA approved label changes for its once-weekly Trulicity injection. The new label was updated to include use in combination with basal insulin for adults with Type 2 diabetes.
The label update was based on results from a phase IIIb randomized clinical trial, Lilly said, which evaluated Trulicity as an add-on to titrated insulin glargine for 28 weeks. The data showed that the Trulicity-insuline glargine combination significantly lowered A1C compared to a placebo with insulin glargine.
Get the full story at our sister site, Drug Delivery Business News.